ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-acting Injectable Antipsychotics (LAIs) Market Research Report 2026
Published Date: 2026-04-10
|
Report Code: QYRE-Auto-16M17038
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Long acting Injectable Antipsychotics LAIs Market Research Report 2024
BUY CHAPTERS

Global Long-acting Injectable Antipsychotics (LAIs) Market Research Report 2026

Code: QYRE-Auto-16M17038
Report
2026-04-10
Pages:111
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Essential Pharma
Janssen Pharmaceuticals
Qilu Pharmaceutical
Alkermes Pharma Ireland Limited
Lvye Pharmaceutical

Long-acting Injectable Antipsychotics (LAIs) Market

The global Long-acting Injectable Antipsychotics (LAIs) market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Long-acting Injectable Antipsychotics (LAIs) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Long-acting injectable (LAI) antipsychotics are unique medication formulations used in psychiatric pharmacy to help improve patient outcomes. They offer several benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability, and prevention of antipsychotic overdose.
The North American market for Long-acting Injectable Antipsychotics (LAIs) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Long-acting Injectable Antipsychotics (LAIs) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Long-acting Injectable Antipsychotics (LAIs) include Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Long-acting Injectable Antipsychotics (LAIs) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Long-acting Injectable Antipsychotics (LAIs). The Long-acting Injectable Antipsychotics (LAIs) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Long-acting Injectable Antipsychotics (LAIs) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Long-acting Injectable Antipsychotics (LAIs) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Long-acting Injectable Antipsychotics (LAIs) Market Report

Report Metric Details
Report Name Long-acting Injectable Antipsychotics (LAIs) Market
Segment by Type
  • First-generation
  • Second-generation
by Application
  • Schizophrenia
  • Bipolar Disorder
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Long-acting Injectable Antipsychotics (LAIs) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Long-acting Injectable Antipsychotics (LAIs) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Long-acting Injectable Antipsychotics (LAIs) Market report?

Ans: The main players in the Long-acting Injectable Antipsychotics (LAIs) Market are Otsuka Pharmaceutical, CHEPLAPHARM Arzneimittel GmbH, Alkermes Pharma Ireland Limited, Essential Pharma, Janssen Pharmaceuticals, Indivior UK Limited, Qilu Pharmaceutical, Lvye Pharmaceutical

What are the Application segmentation covered in the Long-acting Injectable Antipsychotics (LAIs) Market report?

Ans: The Applications covered in the Long-acting Injectable Antipsychotics (LAIs) Market report are Schizophrenia, Bipolar Disorder, Other

What are the Type segmentation covered in the Long-acting Injectable Antipsychotics (LAIs) Market report?

Ans: The Types covered in the Long-acting Injectable Antipsychotics (LAIs) Market report are First-generation, Second-generation

1 Long-acting Injectable Antipsychotics (LAIs) Market Overview
1.1 Product Definition
1.2 Long-acting Injectable Antipsychotics (LAIs) by Type
1.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Type: 2025 vs 2032
1.2.2 First-generation
1.2.3 Second-generation
1.3 Long-acting Injectable Antipsychotics (LAIs) by Application
1.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Application: 2025 vs 2032
1.3.2 Schizophrenia
1.3.3 Bipolar Disorder
1.3.4 Other
1.4 Global Long-acting Injectable Antipsychotics (LAIs) Market Size Estimates and Forecasts
1.4.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue 2021–2032
1.4.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales 2021–2032
1.4.3 Global Long-acting Injectable Antipsychotics (LAIs) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Long-acting Injectable Antipsychotics (LAIs) Market Competition by Manufacturers
2.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Long-acting Injectable Antipsychotics (LAIs) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Long-acting Injectable Antipsychotics (LAIs), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Product Types and Applications
2.7 Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Date of Entry into the Industry
2.8 Global Long-acting Injectable Antipsychotics (LAIs) Market Competitive Situation and Trends
2.8.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Long-acting Injectable Antipsychotics (LAIs) Players Market Share by Revenue
2.8.3 Global Long-acting Injectable Antipsychotics (LAIs) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Injectable Antipsychotics (LAIs) Market Scenario by Region
3.1 Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region: 2021–2032
3.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region: 2021–2026
3.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region: 2027–2032
3.3 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2021–2032
3.3.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2021–2026
3.3.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2027–2032
3.4 North America Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.4.1 North America Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2021–2032)
3.4.3 North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.5.1 Europe Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2021–2032)
3.5.3 Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales by Region (2021–2032)
3.6.3 Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.7.1 Latin America Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2021–2032)
3.7.3 Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2021–2032)
4.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2021–2026)
4.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Type (2027–2032)
4.1.3 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2021–2032)
4.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2021–2032)
4.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2021–2026)
4.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Type (2027–2032)
4.2.3 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2021–2032)
4.3 Global Long-acting Injectable Antipsychotics (LAIs) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2021–2032)
5.1.1 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2021–2026)
5.1.2 Global Long-acting Injectable Antipsychotics (LAIs) Sales by Application (2027–2032)
5.1.3 Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2021–2032)
5.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2021–2032)
5.2.1 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2021–2026)
5.2.2 Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Application (2027–2032)
5.2.3 Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2021–2032)
5.3 Global Long-acting Injectable Antipsychotics (LAIs) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Otsuka Pharmaceutical
6.1.1 Otsuka Pharmaceutical Company Information
6.1.2 Otsuka Pharmaceutical Description and Business Overview
6.1.3 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.1.5 Otsuka Pharmaceutical Recent Developments/Updates
6.2 CHEPLAPHARM Arzneimittel GmbH
6.2.1 CHEPLAPHARM Arzneimittel GmbH Company Information
6.2.2 CHEPLAPHARM Arzneimittel GmbH Description and Business Overview
6.2.3 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.2.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
6.3 Alkermes Pharma Ireland Limited
6.3.1 Alkermes Pharma Ireland Limited Company Information
6.3.2 Alkermes Pharma Ireland Limited Description and Business Overview
6.3.3 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.3.5 Alkermes Pharma Ireland Limited Recent Developments/Updates
6.4 Essential Pharma
6.4.1 Essential Pharma Company Information
6.4.2 Essential Pharma Description and Business Overview
6.4.3 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.4.5 Essential Pharma Recent Developments/Updates
6.5 Janssen Pharmaceuticals
6.5.1 Janssen Pharmaceuticals Company Information
6.5.2 Janssen Pharmaceuticals Description and Business Overview
6.5.3 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.5.5 Janssen Pharmaceuticals Recent Developments/Updates
6.6 Indivior UK Limited
6.6.1 Indivior UK Limited Company Information
6.6.2 Indivior UK Limited Description and Business Overview
6.6.3 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.6.5 Indivior UK Limited Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.7.1 Qilu Pharmaceutical Company Information
6.7.2 Qilu Pharmaceutical Description and Business Overview
6.7.3 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 Lvye Pharmaceutical
6.8.1 Lvye Pharmaceutical Company Information
6.8.2 Lvye Pharmaceutical Description and Business Overview
6.8.3 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product Portfolio
6.8.5 Lvye Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Injectable Antipsychotics (LAIs) Industry Chain Analysis
7.2 Long-acting Injectable Antipsychotics (LAIs) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Injectable Antipsychotics (LAIs) Production Mode & Process Analysis
7.4 Long-acting Injectable Antipsychotics (LAIs) Sales and Marketing
7.4.1 Long-acting Injectable Antipsychotics (LAIs) Sales Channels
7.4.2 Long-acting Injectable Antipsychotics (LAIs) Distributors
7.5 Long-acting Injectable Antipsychotics (LAIs) Customer Analysis
8 Long-acting Injectable Antipsychotics (LAIs) Market Dynamics
8.1 Long-acting Injectable Antipsychotics (LAIs) Industry Trends
8.2 Long-acting Injectable Antipsychotics (LAIs) Market Drivers
8.3 Long-acting Injectable Antipsychotics (LAIs) Market Challenges
8.4 Long-acting Injectable Antipsychotics (LAIs) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Otsuka Pharmaceutical
CHEPLAPHARM Arzneimittel GmbH
Essential Pharma
Janssen Pharmaceuticals
Qilu Pharmaceutical
Alkermes Pharma Ireland Limited
Lvye Pharmaceutical
List of Tables
 Table 1. Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Long-acting Injectable Antipsychotics (LAIs) Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Long-acting Injectable Antipsychotics (LAIs) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Long-acting Injectable Antipsychotics (LAIs), Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Product Types and Applications
 Table 12. Global Key Manufacturers of Long-acting Injectable Antipsychotics (LAIs), Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Long-acting Injectable Antipsychotics (LAIs) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Long-acting Injectable Antipsychotics (LAIs) Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region (K Units), 2021–2026
 Table 18. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2021–2026)
 Table 19. Global Long-acting Injectable Antipsychotics (LAIs) Sales by Region (K Units), 2027–2032
 Table 20. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2027–2032)
 Table 21. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2021–2026)
 Table 23. Global Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2027–2032)
 Table 25. North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2021–2026
 Table 27. North America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2027–2032
 Table 28. North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2021–2026
 Table 32. Europe Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2027–2032
 Table 33. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2021–2026
 Table 42. Latin America Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2027–2032
 Table 43. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Type (2021–2026)
 Table 51. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Type (2027–2032)
 Table 52. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2021–2026)
 Table 53. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Type (2027–2032)
 Table 54. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2021–2026)
 Table 57. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Type (2027–2032)
 Table 58. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Application (2021–2026)
 Table 61. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units) by Application (2027–2032)
 Table 62. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2021–2026)
 Table 63. Global Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Application (2027–2032)
 Table 64. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Long-acting Injectable Antipsychotics (LAIs) Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2021–2026)
 Table 67. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Application (2027–2032)
 Table 68. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Application (2027–2032)
 Table 70. Otsuka Pharmaceutical Company Information
 Table 71. Otsuka Pharmaceutical Description and Business Overview
 Table 72. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Otsuka Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product
 Table 74. Otsuka Pharmaceutical Recent Developments/Updates
 Table 75. CHEPLAPHARM Arzneimittel GmbH Company Information
 Table 76. CHEPLAPHARM Arzneimittel GmbH Description and Business Overview
 Table 77. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. CHEPLAPHARM Arzneimittel GmbH Long-acting Injectable Antipsychotics (LAIs) Product
 Table 79. CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
 Table 80. Alkermes Pharma Ireland Limited Company Information
 Table 81. Alkermes Pharma Ireland Limited Description and Business Overview
 Table 82. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Alkermes Pharma Ireland Limited Long-acting Injectable Antipsychotics (LAIs) Product
 Table 84. Alkermes Pharma Ireland Limited Recent Developments/Updates
 Table 85. Essential Pharma Company Information
 Table 86. Essential Pharma Description and Business Overview
 Table 87. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Essential Pharma Long-acting Injectable Antipsychotics (LAIs) Product
 Table 89. Essential Pharma Recent Developments/Updates
 Table 90. Janssen Pharmaceuticals Company Information
 Table 91. Janssen Pharmaceuticals Description and Business Overview
 Table 92. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Janssen Pharmaceuticals Long-acting Injectable Antipsychotics (LAIs) Product
 Table 94. Janssen Pharmaceuticals Recent Developments/Updates
 Table 95. Indivior UK Limited Company Information
 Table 96. Indivior UK Limited Description and Business Overview
 Table 97. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Indivior UK Limited Long-acting Injectable Antipsychotics (LAIs) Product
 Table 99. Indivior UK Limited Recent Developments/Updates
 Table 100. Qilu Pharmaceutical Company Information
 Table 101. Qilu Pharmaceutical Description and Business Overview
 Table 102. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Qilu Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product
 Table 104. Qilu Pharmaceutical Recent Developments/Updates
 Table 105. Lvye Pharmaceutical Company Information
 Table 106. Lvye Pharmaceutical Description and Business Overview
 Table 107. Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Lvye Pharmaceutical Long-acting Injectable Antipsychotics (LAIs) Product
 Table 109. Lvye Pharmaceutical Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Long-acting Injectable Antipsychotics (LAIs) Distributors List
 Table 113. Long-acting Injectable Antipsychotics (LAIs) Customers List
 Table 114. Long-acting Injectable Antipsychotics (LAIs) Market Trends
 Table 115. Long-acting Injectable Antipsychotics (LAIs) Market Drivers
 Table 116. Long-acting Injectable Antipsychotics (LAIs) Market Challenges
 Table 117. Long-acting Injectable Antipsychotics (LAIs) Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Long-acting Injectable Antipsychotics (LAIs)
 Figure 2. Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Long-acting Injectable Antipsychotics (LAIs) Market Share by Type: 2025 & 2032
 Figure 4. First-generation Product Picture
 Figure 5. Second-generation Product Picture
 Figure 6. Global Long-acting Injectable Antipsychotics (LAIs) Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Long-acting Injectable Antipsychotics (LAIs) Market Share by Application: 2025 & 2032
 Figure 8. Schizophrenia
 Figure 9. Bipolar Disorder
 Figure 10. Other
 Figure 11. Global Long-acting Injectable Antipsychotics (LAIs) Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Long-acting Injectable Antipsychotics (LAIs) Market Size (US$ Million), 2021–2032
 Figure 13. Global Long-acting Injectable Antipsychotics (LAIs) Sales (K Units), 2021–2032
 Figure 14. Global Long-acting Injectable Antipsychotics (LAIs) Average Price (US$/Unit), 2021–2032
 Figure 15. Long-acting Injectable Antipsychotics (LAIs) Report Years Considered
 Figure 16. Long-acting Injectable Antipsychotics (LAIs) Sales Share by Manufacturers in 2025
 Figure 17. Global Long-acting Injectable Antipsychotics (LAIs) Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Long-acting Injectable Antipsychotics (LAIs) Players: Market Share by Revenue in Long-acting Injectable Antipsychotics (LAIs) in 2025
 Figure 19. Long-acting Injectable Antipsychotics (LAIs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Long-acting Injectable Antipsychotics (LAIs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2021–2032)
 Figure 22. North America Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2021–2032)
 Figure 23. United States Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2021–2032)
 Figure 26. Europe Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Region (2021–2032)
 Figure 34. China Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2021–2032)
 Figure 42. Latin America Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Long-acting Injectable Antipsychotics (LAIs) Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Long-acting Injectable Antipsychotics (LAIs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Long-acting Injectable Antipsychotics (LAIs) by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Long-acting Injectable Antipsychotics (LAIs) by Type (2021–2032)
 Figure 54. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Long-acting Injectable Antipsychotics (LAIs) by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Long-acting Injectable Antipsychotics (LAIs) by Application (2021–2032)
 Figure 57. Global Long-acting Injectable Antipsychotics (LAIs) Price (US$/Unit) by Application (2021–2032)
 Figure 58. Long-acting Injectable Antipsychotics (LAIs) Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Long Acting Injectable LAI Antipsychotic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Long acting Injectable Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Long Acting Schizophrenia Drug Market Research Report 2024
Global Long acting Antipsychotic Market Research Report 2024
Global Psychiatric Long acting Injection Market Research Report 2024
Antipsychotics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Paliperidone Palmitate Injection Market Research Report 2024
Global Olanzapine Tablets Market Research Report 2024
Global Ziprasidone Mesylate for Injection Market Research Report 2024
Global Risperidone Microspheres for Injection Market Research Report 2024
Global Antipsychotic Medications Market Research Report 2024
Neuroleptics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ziprasidone Drugs Market Research Report 2024
Global Risperidone API Market Research Report 2025
Global Antipsychotic Drug Market Research Report 2024
Global Quetiapine Fumarate Market Insights Forecast to 2030
Global Long Acting Contraceptive Pills Market Research Report 2024
Global Clozapine Oral Suspension Market Research Report 2024
Global Risperidone Market Research Report 2024
Global Chlorpromazine Hydrochloride Tablets Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions